Q1 Earnings Estimate for EWTX Issued By HC Wainwright

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) – Stock analysts at HC Wainwright issued their Q1 2026 earnings estimates for Edgewise Therapeutics in a research report issued to clients and investors on Thursday, February 26th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings per share of ($0.43) for the quarter. The consensus estimate for Edgewise Therapeutics’ current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Edgewise Therapeutics’ Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.51) EPS and Q4 2026 earnings at ($0.60) EPS.

Edgewise Therapeutics (NASDAQ:EWTX) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.04).

Several other brokerages have also recently weighed in on EWTX. Wedbush decreased their price target on Edgewise Therapeutics from $35.00 to $32.00 and set an “outperform” rating for the company in a research note on Friday, November 7th. Wall Street Zen raised shares of Edgewise Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, February 15th. Royal Bank Of Canada raised their price target on shares of Edgewise Therapeutics from $49.00 to $50.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Evercore reaffirmed an “outperform” rating and issued a $45.00 price objective on shares of Edgewise Therapeutics in a research note on Thursday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Edgewise Therapeutics in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $36.36.

Edgewise Therapeutics Trading Down 1.5%

Shares of EWTX opened at $29.66 on Friday. The company has a market capitalization of $3.14 billion, a PE ratio of -18.77 and a beta of 0.27. Edgewise Therapeutics has a 12 month low of $10.60 and a 12 month high of $31.82. The stock’s 50-day moving average price is $27.53 and its two-hundred day moving average price is $21.05.

Insider Activity at Edgewise Therapeutics

In other news, Director Badreddin Edris sold 115,471 shares of the firm’s stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $29.44, for a total transaction of $3,399,466.24. Following the completion of the sale, the director owned 19,820 shares of the company’s stock, valued at $583,500.80. This trade represents a 85.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 23.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Edgewise Therapeutics

A number of large investors have recently bought and sold shares of the stock. Seven Fleet Capital Management LP bought a new stake in Edgewise Therapeutics in the fourth quarter valued at $50,000. Jones Financial Companies Lllp bought a new stake in Edgewise Therapeutics in the 1st quarter valued at about $47,000. Bessemer Group Inc. increased its position in Edgewise Therapeutics by 1,170.3% in the 3rd quarter. Bessemer Group Inc. now owns 2,350 shares of the company’s stock valued at $38,000 after buying an additional 2,165 shares in the last quarter. Steward Partners Investment Advisory LLC raised its stake in Edgewise Therapeutics by 23.9% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,854 shares of the company’s stock worth $71,000 after buying an additional 550 shares during the period. Finally, Canada Pension Plan Investment Board bought a new position in Edgewise Therapeutics in the second quarter worth approximately $45,000.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.